Your browser doesn't support javascript.
loading
A meta-analysis of effectiveness of real-world studies of antipsychotics in schizophrenia: Are the results consistent with the findings of randomized controlled trials?
Katona, Lajos; Bitter, István; Czobor, Pál.
Affiliation
  • Katona L; Independent Researcher, Budapest, Hungary.
  • Bitter I; Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary.
  • Czobor P; Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary. czobor.pal@med.semmelweis-univ.hu.
Transl Psychiatry ; 11(1): 510, 2021 10 06.
Article in En | MEDLINE | ID: mdl-34615850
ABSTRACT
Randomized controlled trials (RCTs) have been considered as gold standard for establishing the efficacy and safety of investigational new drugs; nonetheless, the generalizability of their findings has been questioned. To address this issue, an increasing number of naturalistic studies and real-world database analyses have been conducted. The question of how much information from these two approaches is congruent or discrepant with each other is of great importance for the clinical practice. To answer this question, we focused on data from the antipsychotic (AP) treatment of schizophrenia. Our aim was two-fold to conduct a meta-analysis of real-world studies (RWS), and to compare the results of RWS meta-analysis with previously published meta-analyses of RCTs. The principal measure of effectiveness was all-cause treatment discontinuation for both RWS and RCTs (when not available, then drop out for RCTs). We included publications for 8 selected APs (oral formulations of amisulpride, aripiprazole, clozapine, haloperidol, olanzapine, quetiapine, risperidone, and long-acting injectable (LAI) risperidone). We identified 11 RWS and 7 RCT meta-analyses for inclusion. Our results indicated that the RWS yielded statistically conclusive and consistent findings across individual investigations. For the overwhelming majority of the comparisons where both RWS and RCT meta-analyses were available, there was good congruency between the RWS and the RCT results. Our results support that RCTs, despite their limitations, provide evidence which is generalizable to real-world settings. This is an important finding for both regulators and clinicians. RWS can provide guidance for situations where no evidence is available from double-blind clinical trials.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Schizophrenia / Antipsychotic Agents Type of study: Clinical_trials / Diagnostic_studies / Guideline / Prognostic_studies / Systematic_reviews Limits: Humans Language: En Journal: Transl Psychiatry Year: 2021 Document type: Article Affiliation country: Hungary

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Schizophrenia / Antipsychotic Agents Type of study: Clinical_trials / Diagnostic_studies / Guideline / Prognostic_studies / Systematic_reviews Limits: Humans Language: En Journal: Transl Psychiatry Year: 2021 Document type: Article Affiliation country: Hungary